Polar Asset Management Partners’s NRX Pharmaceuticals NRXP Stock Holding History

Polar Asset Management Partners’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-51,750	Closed	-$5.49M	–	467
2019 Q4	$5.49M	Hold	51,750	–	–	0.11%	213
2019 Q3	$5.47M	Hold	51,750	–	–	0.1%	194
2019 Q2	$5.45M	Buy	51,750 +34,920	+207%	+$3.63M	0.1%	178
2019 Q1	$1.74M	Sell	16,830 -30,000	-64%	-$3.08M	0.04%	217
2018 Q4	$4.78M	Hold	46,830	–	–	0.09%	170
2018 Q3	$4.69M	Hold	46,830	–	–	0.09%	177
2018 Q2	$4.64M	Buy	46,830 +3,750	+9%	+$370K	0.08%	195
2018 Q1	$4.23M	Hold	43,080	–	–	0.07%	194
2017 Q4	$4.18M	Buy	+43,080	New	+$4.17M	0.07%	216

Other funds holding NRXP

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BCM

Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Polar Asset Management Partners's NRXP Position: Q1 2020 in Review

Polar Asset Management Partners sold out of NRX Pharmaceuticals (NRXP) in Q1 2020, closing a stake of 51,750 shares — an estimated $5.49M sold.

Polar Asset Management Partners first reported a position in NRXP in Q4 2017 and held it in 9 quarters. The position peaked at $5.49M in Q4 2019. 7 funds tracked by Wall St. Rank hold NRXP as of Q1 2020.

Polar Asset Management Partners reported no remaining NRX Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Polar Asset Management Partners sold 51,750 NRX Pharmaceuticals shares in Q1 2020, an estimated $5.49M.
Polar Asset Management Partners first reported a position in NRX Pharmaceuticals in Q4 2017 and held it in 9 quarters.
Polar Asset Management Partners's NRX Pharmaceuticals position peaked at $5.49M in Q4 2019.
7 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2020.

Based on Polar Asset Management Partners's 13F filing for Q1 2020, filed 15 May 2020.